Paul Koevoets

Company: Vico Therapeutics

Job title: Director Anal Chemistry

Seminars:

Impurity Profiling of VO659, VICO’s Antisense Oligonucleotide for the Treatment of PolyQ Diseases 12:00 pm

Case study looking into VO659 antisense oligonucleotide which is in clinical trials for Huntington’s Disease, SCA1 and SCA3 Utilizing LC-UV-MS for impurity profiling Qualifying levels of impurities in oligo drugsRead more

day: Day One AM